迪哲医药(688192) - 2024 Q4 - 年度业绩

Financial Performance - In 2024, the company achieved total operating revenue of 360.39 million yuan, a significant increase of 294.79% compared to the previous year[5] - The net loss attributable to the parent company was 856.77 million yuan, a reduction of 250.94 million yuan from the previous year[9] - The company’s basic earnings per share were -2.07 yuan, an improvement from -2.72 yuan in the previous year[5] - The weighted average return on net assets was -164.88%, down from -84.95% in the previous year[5] - The company’s equity attributable to shareholders decreased by 78.44% to 182.94 million yuan[5] Assets and Investments - The company’s total assets at the end of the reporting period were 1,718.86 million yuan, reflecting a 14.87% increase from the beginning of the period[5] - The company continues to invest heavily in R&D, with ongoing clinical trials for multiple products, including DZD8586 and DZD6008[9] Market Developments - The company’s core products, Shuwozhe® and Gaoruizhe®, were included in the National Medical Insurance Drug List, effective January 1, 2025, enhancing their market accessibility[7] - The company completed a price compensation for distributors due to significant price reductions after entering the National Medical Insurance Drug List, impacting Q4 sales[8] Future Outlook - The company expects to maintain a negative net profit situation due to high R&D expenditures despite significant revenue growth[10]